Emerging health care tech opportunities post COVID - FNDX Given the ongoing global impact of COVID-19, there is a heightened awareness of the potential for future pandemics or epidemics. As a result, there is a growing demand for products that can effectively mitigate the transmission of viruses and bacteria. FendX Technologies Inc. (FNDX.C) is developing advanced solutions using proprietary nanotechnology that can prevent pathogen transmission.
One of the main things that position FNDX for success within the healthcare product market is its highly experienced leadership. FNDX's CEO has experience creating and growing healthcare businesses. She is a Principal at BioEnsemble LLC, where she works with small pharma companies and start-ups to develop business strategies. Additionally, FNDX's COO has done sales and marketing for leading pharmaceutical and biotechnology corporations in Canada.
FNDX's flagship product is REPELWRAP™ film, a coating that can be adhered to surfaces to make bacteria and viruses bounce off of them. Because REPELWRAP™ does not kill pathogens like disinfectants, its use is not expected to contribute to antibiotic resistance or create superbugs.
With its impressive leadership and technology, FNDX is well-positioned to meet the rising demand for pathogen-preventing products when it launches REPELWRAP™ film in 2024.
More information here: https://fendxtech.com Posted on behalf of FendX Technologies Inc.